Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1L | First line |
| 1LOT | First line of therapy |
| 2H | Second half (of a calendar year) |
| 2L | Second line of therapy |
| 2LOT | Second line of therapy |
| 3D | Three-dimensional |
| 3L | Third line |
| 3LOT | Third line of therapy |
| 5-FU | Fluorouracil |
| 5FU | Fluorouracil |
| 7MM | Seven major markets |
| ABC | Advanced biliary cancer |
| ABC-06 | Advanced Biliary Cancer 06 trial |
| ABL Bio | ABL Bio, Inc. |
| ABL001 | Development code for tovecimig used by ABL Bio |
| ABT-165 | Development code for dilpacimab |
| AHFS | American Hospital Formulary Service |
| aHR | Adjusted hazard ratio |
| AJCC | American Joint Committee on Cancer |
| AoV | Ampulla of Vater |
| ARID1 | AT-rich interaction domain 1 |
| ARID1A | AT-rich interaction domain 1A |
| ASC | Active symptom control |
| ASCO | American Society of Clinical Oncology |
| ASCO GI | American Society of Clinical Oncology Gastrointestinal Cancers Symposium |
| ASP | Average sales price |
| ATC | Anatomical Therapeutic Chemical classification |
| BAP1 | BRCA1-associated protein 1 |
| BICR | Blinded independent central review |
| BLA | Biologics license application |
| BNP | B-type natriuretic peptide |
| BOR | Best overall response |
| BRAF | B-Raf proto-oncogene, serine/threonine kinase |
| BTC | Biliary tract cancer |
| BTT | Biliary tract tumor |
| CA 19-9 | Carbohydrate antigen 19-9 |
| CA125 | Cancer antigen 125 |
| CA19-9 | Carbohydrate antigen 19-9 |
| CCA | Cholangiocarcinoma |
| CD31 | Cluster of differentiation 31 (platelet endothelial cell adhesion molecule 1) |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CEA | Carcinoembryonic antigen |
| CGP | Comprehensive genomic profiling |
| CHF | Congestive heart failure |
| ChT | Chemotherapy |
| CI | Confidence interval |
| CMS | Centers for Medicare and Medicaid Services |
| CNS | Central nervous system |
| COMPANION-002 | Phase 2/3 randomized trial of tovecimig plus paclitaxel in second-line biliary tract cancer |
| cORR | Confirmed objective response rate |
| CR | Complete response |
| CRC | Colorectal cancer |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTX-009 | Development code for tovecimig used by Compass Therapeutics |
| CTX-10726 | Investigational PD-1 by VEGF-A bispecific antibody |
| CTX-471 | Investigational CD137 (4-1BB) agonist antibody |
| CTX-8371 | Investigational PD-1 by PD-L1 bispecific antibody |
| CUP | Cancer of unknown primary |
| DBP | Diastolic blood pressure |
| dCCA | Distal cholangiocarcinoma |
| DCR | Disease control rate |
| DLL4 | Delta-like ligand 4 |
| DLT | Dose-limiting toxicity |
| DMC | Data Monitoring Committee |
| dMMR | Mismatch repair deficient |
| DOR | Duration of response |
| DoR | Duration of response |
| EAG | External assessment group |
| eAPC | Estimated annual percent change |
| ECC | Extrahepatic cholangiocarcinoma |
| eCCA | Extrahepatic cholangiocarcinoma |
| ECG | Electrocardiogram |
| ECM | Extracellular matrix |
| ECOG | Eastern Cooperative Oncology Group |
| EGF | Epidermal growth factor |
| EHCC | Extrahepatic cholangiocarcinoma |
| ELF3 | E74-like factor 3 |
| ELISA | Enzyme-linked immunosorbent assay |
| EMA | European Medicines Agency |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EORTC QLQ-C30 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 |
| EQ-5D | EuroQol 5 Dimension |
| ERBB | Erythroblastic oncogene B |
| ERC | Endoscopic retrograde cholangiography |
| ERCP | Endoscopic retrograde cholangiopancreatography |
| ESCAT | ESMO Scale for Clinical Actionability of Molecular Targets |
| ESMO | European Society for Medical Oncology |
| ESMO-MCBS | European Society for Medical Oncology Magnitude of Clinical Benefit Scale |
| EU4 | Germany, France, Italy and Spain |
| EUS | Endoscopic ultrasonography |
| FDA | US Food and Drug Administration |
| FDG-PET | Fluorodeoxyglucose positron emission tomography |
| FGFR | Fibroblast growth factor receptor |
| FGFR2 | Fibroblast growth factor receptor 2 |
| FISH | Fluorescence in situ hybridization |
| FNA | Fine-needle aspiration |
| FOLFIRI | Folinic acid, fluorouracil, and irinotecan |
| FOLFOX | Folinic acid, fluorouracil, and oxaliplatin |
| FTD | Fast Track designation |
| Fv | Variable fragment |
| GAP | Gemcitabine, cisplatin, and nab-paclitaxel |
| GB | Gallbladder cancer |
| GBC | Gallbladder cancer |
| GC | Gemcitabine and cisplatin; gastric cancer |
| GCD | Gemcitabine, cisplatin, and durvalumab |
| GemCis | Gemcitabine and cisplatin |
| GEO | Gene Expression Omnibus |
| GI | Gastrointestinal |
| GLOBOCAN | Global Cancer Observatory estimates of cancer incidence and mortality |
| HCC | Hepatocellular carcinoma |
| HCRU | Healthcare resource utilization |
| hDLL4 | Human delta-like ligand 4 |
| HER2 | Human epidermal growth factor receptor 2 |
| HES1 | Hes family basic helix-loop-helix transcription factor 1 |
| HR | Hazard ratio |
| IBD | Inflammatory bowel disease |
| ICC | Intrahepatic cholangiocarcinoma |
| iCCA | Intrahepatic cholangiocarcinoma |
| ICER | Incremental cost-effectiveness ratio |
| ICR | Independent central review |
| IDH | Isocitrate dehydrogenase |
| IDH1 | Isocitrate dehydrogenase 1 |
| IDH2 | Isocitrate dehydrogenase 2 |
| IgG | Immunoglobulin G |
| IHC | Immunohistochemistry |
| IHCC | Intrahepatic cholangiocarcinoma |
| IL-1β | Interleukin 1 beta |
| ILD | Interstitial lung disease |
| INHB | Incremental net health benefit |
| INMB | Incremental net monetary benefit |
| IQR | Interquartile range |
| IRB | Institutional review board |
| IST | Investigator-sponsored trial |
| ITT | Intention to treat |
| IUD | Intrauterine device |
| IV | Intravenous |
| KEYNOTE-966 | KEYNOTE-966 trial |
| KPS | Karnofsky performance status |
| KRAS | Kirsten rat sarcoma viral oncogene homolog |
| LDP | Limited-duration prevalence |
| LoE | Level of evidence |
| LOT | Line of therapy |
| LV | Leucovorin |
| LVEF | Left ventricular ejection fraction |
| LY3039478 | Crenigacestat development code |
| mAb | Monoclonal antibody |
| mABL001 | Mouse surrogate version of ABL001 |
| mBTC | Metastatic biliary tract cancer |
| MCBS | ESMO-Magnitude of Clinical Benefit Scale |
| MDTB | Multidisciplinary tumor board |
| mFOLFOX | Modified folinic acid, fluorouracil and oxaliplatin |
| MMP13 | Matrix metalloproteinase 13 |
| MRCP | Magnetic resonance cholangiopancreatography |
| MRI | Magnetic resonance imaging |
| MSI-H | Microsatellite instability high |
| MTD | Maximum tolerated dose |
| MYC | MYC proto-oncogene |
| nab-paclitaxel | Nanoparticle albumin-bound paclitaxel |
| NAFLD | Non-alcoholic fatty liver disease |
| nal-IRI | Liposomal irinotecan |
| NCI | National Cancer Institute |
| NE | Not estimable, or not evaluable where used for response category |
| NHS | National Health Service |
| NICE | National Institute for Health and Care Excellence |
| NOAEL | No observed adverse effect level |
| NOTCH1 | Neurogenic locus notch homolog protein 1 |
| NOV1501 | Development code for tovecimig used under the National OncoVenture program |
| NR | Not reached |
| NT | New Taiwan dollar |
| NTRK | Neurotrophic tyrosine receptor kinase |
| NYHA | New York Heart Association |
| ODD | Orphan drug designation |
| OFV | Objective function value |
| OMP-305B83 | Development code for navicixizumab |
| OR | Odds ratio |
| ORR | Objective response rate, also reported as overall response rate |
| OS | Overall survival |
| OS12 | Overall survival rate at 12 months |
| p-y | Person-years |
| PBRM1 | Polybromo 1 |
| pCCA | Perihilar cholangiocarcinoma |
| PD | Progressive disease |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PDGF | Platelet-derived growth factor |
| PFS | Progression-free survival |
| PFS1 | Progression-free survival before crossover |
| PFS2 | Progression-free survival after crossover |
| PK | Pharmacokinetics |
| PPPM | Per patient per month |
| PR | Partial response |
| PRKACA | Protein kinase cAMP-activated catalytic subunit alpha |
| PRKACB | Protein kinase cAMP-activated catalytic subunit beta |
| PRKCA | Protein kinase C alpha |
| PRKCB | Protein kinase C beta |
| PS | Performance status |
| PSA | Probabilistic sensitivity analysis |
| PTBD | Percutaneous transhepatic biliary drain |
| PTC | Percutaneous transhepatic cholangiography |
| Q | Intercompartmental clearance |
| Q3 | Third quarter of a calendar year |
| Q4 | Fourth quarter of a calendar year |
| QALY | Quality-adjusted life-year |
| QLQ-BIL21 | EORTC Quality of Life Questionnaire, Cholangiocarcinoma and Gallbladder Cancer Module, 21 items |
| QLQ-C30 | EORTC Quality of Life Questionnaire Core 30 |
| QoL | Quality of life |
| QT | QT interval on the electrocardiogram |
| QTcF | QT interval corrected for heart rate by Fridericia's formula |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RET | Ret proto-oncogene |
| RP2D | Recommended phase 2 dose |
| RPSFT | Rank-preserving structural failure time |
| S-1 | Tegafur, gimeracil, and oteracil |
| SBP | Systolic blood pressure |
| SBRT | Stereotactic body radiotherapy |
| scFv | Single-chain variable fragment |
| SD | Stable disease; standard deviation |
| SDF1 | Stromal cell-derived factor 1 |
| SEER | Surveillance, Epidemiology, and End Results |
| SMAD4 | SMAD family member 4 |
| TA1153 | NICE technology appraisal guidance 1153 |
| TAM | Total addressable market |
| TEAE | Treatment-emergent adverse event |
| TGI | Tumor growth inhibition |
| TMB-H | Tumor mutational burden-high |
| TME | Tumour microenvironment |
| TNF | Tumour necrosis factor |
| TNM | Tumour, node, metastasis |
| TOPAZ-1 | TOPAZ-1 trial |
| TP53 | Tumour protein p53 |
| TR009 | Development code for tovecimig used by TRIGR Therapeutics |
| TRAE | Treatment-related adverse event |
| TRIGR | Trigr Therapeutics, Inc. |
| TTD | Time to deterioration |
| TTF | Time to treatment failure |
| ULN | Upper limit of normal |
| US | United States |
| USA | United States of America |
| USD | United States dollar |
| V1 | Volume of distribution of the central compartment |
| VEGF | Vascular endothelial growth factor |
| VEGF-A | Vascular endothelial growth factor A |
| VEGF-C | Vascular endothelial growth factor C |
| VEGFA | Vascular endothelial growth factor A gene |
| VEGFR | Vascular endothelial growth factor receptor |
| VEGFR-2 | Vascular endothelial growth factor receptor 2 |
| WHO | World Health Organization |
| WTP | Willingness to pay |